Standard BioTools Inc. (FLDM) |
|
3.71 -0.28 (-7.02%)
|
04-06 00:00 |
|
Open: |
4.05 |
Pre. Close: |
3.99 |
|
High:
|
3.99 |
Low:
|
3.66 |
|
Volume:
|
522,109 |
Market Cap:
|
294(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:20:37 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.55 One year: 4.73 |
| Support: |
Support1: 3.66 Support2: 3.04 |
| Resistance: |
Resistance1: 3.9 Resistance2: 4.05 |
| Pivot: |
3.71 |
| Moving Average: |
MA(5): 3.71 MA(20): 3.71
MA(100): 3.71 MA(250): 3.54  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 12.8 %D(3): 12.8 |
| RSI: |
RSI(14): 64.7 |
| 52-week: |
High: 4.84 Low: 1.63 |
| Average Vol(K): |
3-Month: 522 (K) 10-Days: 522 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FLDM ] has closed Bollinger Bands are 0% narrower than normal. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.06 - 4.08 |
4.08 - 4.1 |
|
Low:
|
3.61 - 3.63 |
3.63 - 3.65 |
|
Close:
|
3.67 - 3.71 |
3.71 - 3.74 |
|
Company Description |
|
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. |
Headline News |
Mon, 04 Apr 2022
Fluidigm Completes $250 Million Strategic Capital Infusion and ... - GlobeNewswire
Fri, 01 Apr 2022
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion - GlobeNewswire
Thu, 17 Feb 2022
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial ... - GlobeNewswire
Wed, 26 Jan 2022
Fluidigm Corporation Stock: Investment Opportunity (NASDAQ:FLDM) - Seeking Alpha
Mon, 24 Jan 2022
Fluidigm announces $250M investment, rebranding to Standard ... - Seeking Alpha
Sat, 24 Aug 2019
The 10X Genomics IPO and Single-Cell Sequencing - Nanalyze
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
77 (M) |
| Shares Float |
53 (M) |
|
% Held by Insiders
|
1.9 (%) |
|
% Held by Institutions
|
99.9 (%) |
|
Shares Short
|
5,630 (K) |
|
Shares Short P.Month
|
5,500 (K) |
Stock Financials |
|
EPS
|
-0.79 |
|
EPS Est Next Qtl
|
-0.35 |
|
EPS Est This Year
|
-1.96 |
|
EPS Est Next Year
|
-1.3 |
|
Book Value (p.s.)
|
1.23 |
|
Profit Margin (%)
|
-45.4 |
|
Operating Margin (%)
|
-51.7 |
|
Return on Assets (ttm)
|
-14.1 |
|
Return on Equity (ttm)
|
-50.8 |
|
Qtrly Rev. Growth
|
-14.2 |
|
Gross Profit (p.s.)
|
0.4 |
|
Sales Per Share
|
1.69 |
|
EBITDA (p.s.)
|
-0.83 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-44 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-4.75 |
|
PEG Ratio
|
0.5 |
|
Price to Book value
|
3.01 |
|
Price to Sales
|
2.19 |
|
Price to Cash Flow
|
-6.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
